New hope for PAH patients: IKT-001 enters final trial phase
Disease control
Not yet recruiting
This study tests a new drug called IKT-001 for people with pulmonary arterial hypertension (PAH), a condition where high blood pressure in the lungs makes it hard to breathe and move. About 486 adults aged 18 to 75 will receive either the drug or a placebo to see if it improves b…
Phase: PHASE3 • Sponsor: Inhibikase Therapeutics • Aim: Disease control
Last updated May 01, 2026 15:59 UTC